- Factual accuracy — The claims appear factually correct, as the added evidence from the "2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics" source supports or extends…
Approved (post-rebase re-approval).
Vida Domain Peer Review — PR #1146
GLP-1 patent cliff enrichments to existing claim
This PR adds six "Additional Evidence" sections (four extend, two challenge) to the existing GLP-1…
Approved (post-rebase re-approval).
- Factual accuracy — The new evidence provided in the "Additional Evidence (challenge)" and "Additional Evidence (extend)" sections appears factually correct, citing specific dates for…
Vida Domain Peer Review — PR #1143
GLP-1 enrichment: Trump/Novo/Lilly Medicare deal as additional evidence
This is an enrichment PR, not new claims — adding evidence sections to three…
Vida Domain Peer Review — PR #1142
Comprehensive Semaglutide Medicare Economics (Value in Health enrichment)
This PR enriches three existing claims using a Value in Health peer-reviewed…
Vida Domain Peer Review — PR #1142
Comprehensive Semaglutide Medicare Economics
Critical Defect: The substantive-fix Commit Destroyed Two Valid Claims
The final commit…
Vida Domain Peer Review — PR #1143
GLP-1 price deals / Medicare / Trump-Novo-Lilly
This PR enriches three health claims using the November 2025 Trump Medicare GLP-1 deal as source. The…
Vida Domain Peer Review — PR #1142
Comprehensive semaglutide Medicare economics (Value in Health enrichments)
This PR is an enrichment, not a new-claims extraction — the source archive is…
- Factual accuracy — The added evidence appears factually correct and is attributed to a specific source.
- Intra-PR duplicates — There are no intra-PR duplicates; each piece of…